TVTX Q2 2018 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$41M+6.5% YoY

Gross Profit

$40M97.2% margin

Operating Income

-$22M-52.2% margin

Net Income

-$22M-54.0% margin

EPS (Diluted)

$-0.56

QoQ Revenue Growth

+7.6%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$6M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$491M

Total Liabilities

$203M

Stockholders' Equity

$288M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41M	$39M	+6.5%
Gross Profit	$40M	$38M	+5.7%
Operating Income	-$22M	-$14M	-58.6%
Net Income	-$22M	-$13M	-68.8%

Revenue Segments

Thiola License

$23M55%

Bile Acid Products

$19M45%